logo

For the Inventor, By the Inventor

New York, NY, United States of America

Imclone LLC

Calculating rank
USPTO Granted Patents = 26

% Expired Patents = 69.2



Trademarks = 5

Forward Citations = 166

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Dale Lincoln Ludwig (4 out of 18 patents)

silverMedal Haijun Sun (4 out of 4 patents)

bronzeMedal Yan Wu (3 out of 111 patents)

4.  Zhenping Zhu (3 out of 11 patents)

5.  Nick Loizos (3 out of 3 patents)

6.  Ling Liu (2 out of 15 patents)

7.  Juqun Shen (2 out of 5 patents)

8.  Paul J Balderes (2 out of 2 patents)

9.  Bronislaw Pytowski (2 out of 3 patents)

10.  Krishnadatt Persaud (2 out of 2 patents)

11.  Nathalie Zayek (2 out of 2 patents)

12.  Jim Huber (2 out of 2 patents)

13.  James Robert Tonra (2 out of 2 patents)

14.  Peter Bohlen (2 out of 3 patents)

15.  Daniel Pereira (2 out of 2 patents)


Core Competencies:
Anti-VEGFR2
FGFR3
PDGFR
Anti-TGF-beta
c-Kit
CSF-1R
FLT3
KDR
IGF-IR
TYRP1
RON
Human Antibodies

26 patents:

1. 10766961 - Anti-VEGFR2 antibody therapy for hepatocellular carcinoma (2020-09-08),
2. 9375488 - Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment (2016-06-28),
3. 8784818 - Anti-VEGFR-3 antibody compositions (2014-07-22),
4. 8574578 - Antibodies against PDGFRα to inhibit tumor growth (2013-11-05),
5. 8552157 - c-Kit antibodies and uses thereof (2013-10-08),
6. 8481034 - Anti-VEGFR-3 antibody compositions (2013-07-09),
7. 8425911 - Methods of treating secondary bone tumors with antibodies against PDGFR alpha (2013-04-23),
8. 8404240 - Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment (2013-03-26),
9. 8263079 - Antibodies against CSF-1R (2012-09-11),
10. 8263074 - Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof (2012-09-11),
11. 8182815 - Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment (2012-05-22),
12. 8147834 - Anti-TGF-beta receptor II antibodies (2012-04-03),
13. 8143025 - Antibodies against vascular endothelial growth factor receptor-1 (2012-03-27),
14. 8133489 - Inhibition of macrophage-stimulating protein receptor (RON) and methods of treatment thereof (2012-03-13),
15. 8128929 - Antibodies against PDGFRa (2012-03-06),
Company Overview
ImClone LLC is a biopharmaceutical company based in New York, specializing in the development of innovative cancer therapies. The organization focuses on targeted treatments that leverage advanced biotechnology to improve patient outcomes. With a commitment to research and development, ImClone is dedicated to addressing unmet medical needs in oncology, utilizing cutting-edge science to create effective solutions for complex health challenges. Its strategic initiatives aim to enhance therapeutic options for patients globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Imclone LLC USPTO Patent Assignee Logo
26 Patents

#330 in New York, NY

#767 in New York

#12,875 in US

#24,848 in the World

New York, NY (US)
New York, NY, United States of America

Imclone LLC

Forward Citations = 166

40 inventors:

goldMedal Dale Lincoln Ludwig (4 out of 18 patents)

silverMedal Haijun Sun (4 out of 4 patents)

bronzeMedal Yan Wu (3 out of 111 patents)

4.  Zhenping Zhu (3 out of 11 patents)

5.  Nick Loizos (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Imclone LLC. Retrieved from https://idiyas.com/company/imclone

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…